Phase II study of edatrexate in advanced head and neck cancer. A Southwest Oncology Group study.
Fifty-two patients with persistent, recurrent and/or metastatic squamous cell cancer of the head and neck were treated with weekly edatrexate, 80 mg/m2. Nine patients had received previous adjuvant or neoadjuvant chemotherapy. Of the 46 eligible patients, two complete responses and one partial response were observed (6%, 95% confidence interval of 1-18%). The most common toxicities were myelosuppression and mucositis, but dermatologic toxicity was also observed in 25% of patients. Edatrexate appears to have limited activity in advanced head and neck cancer.
Kuebler
J P
JP
Riverside Methodist Hospitals, Columbus, OH, USA.
Benedetti
J
J
Schuller
D E
DE
Ensley
J
J
Grunberg
S M
SM
Muirhead
M J
MJ
Richert-Boe
K E
KE
Marshall
M E
ME
D000328:Adult; D000368:Aged; D000630:Aminopterin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy
D000970:Antineoplastic Agents; C040210:edatrexate; D000630:Aminopterin